Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 16;19(1):263.
doi: 10.3390/ijms19010263.

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Affiliations
Review

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Ana M L Seca et al. Int J Mol Sci. .

Abstract

Cancer is a multistage process resulting in an uncontrolled and abrupt division of cells and is one of the leading causes of mortality. The cases reported and the predictions for the near future are unthinkable. Food and Drug Administration data showed that 40% of the approved molecules are natural compounds or inspired by them, from which, 74% are used in anticancer therapy. In fact, natural products are viewed as more biologically friendly, that is less toxic to normal cells. In this review, the most recent and successful cases of secondary metabolites, including alkaloid, diterpene, triterpene and polyphenolic type compounds, with great anticancer potential are discussed. Focusing on the ones that are in clinical trial development or already used in anticancer therapy, therefore successful cases such as paclitaxel and homoharringtonine (in clinical use), curcumin and ingenol mebutate (in clinical trials) will be addressed. Each compound's natural source, the most important steps in their discovery, their therapeutic targets, as well as the main structural modifications that can improve anticancer properties will be discussed in order to show the role of plants as a source of effective and safe anticancer drugs.

Keywords: anticancer therapy; betulinic acid; clinical trial; curcumin; homoharringtonine; ingenol mebutate; paclitaxel; secondary metabolites; vincristine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of the vinca alkaloid vincristine (1), an anticancer natural agent that repress cell growth by altering the microtubular dynamics.
Figure 2
Figure 2
Chemical structure of paclitaxel (2), a natural microtubule inhibitor, and of its precursors baccatin III (3) and 10-deacetylbaccatin III (4).
Figure 3
Figure 3
The parts of the paclitaxel (2) structure that could be modified without loss of activity and two of its derivatives, docetaxel (5) and cabazitaxel (6), available on the market for clinical use.
Figure 4
Figure 4
Chemical structure of homoharringtonine also named omacetaxine mepesuccinate (7) with alkaloid nucleus cephalotaxine (red).
Figure 5
Figure 5
Chemical structure of the diterpene ingenol mebutate (8).
Figure 6
Figure 6
Chemical structure of the polyphenol curcumin (9).
Figure 7
Figure 7
The chemical structure of the pentacyclic triterpene betulinic acid (10) and the main target to structural modifications (red).

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:359–386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. World Health Organization . Cancer: Fact Sheets. WHO; Geneva, Switzerland: 2017. [(accessed on 2 October 2017)]. Available online: http://www.who.int/mediacentre/factsheets/fs297/en/
    1. Bray F. Transitions in human development and the global cancer burden. In: Stewart B.W., Wild C.P., editors. World Cancer Report 2014. International Agency for Research on Cancer; Lyon, France: 2014. pp. 54–68.
    1. Adeloye D., David R.A., Aderemi A.V., Iseolorunkanmi A., Oyedokun A., Iweala E.E., Omoregbe N., Ayo C.K. An estimate of the incidence of prostate cancer in Africa: A systematic review and meta-analysis. PLoS ONE. 2016;11:e0153496. doi: 10.1371/journal.pone.0153496. - DOI - PMC - PubMed

Substances

LinkOut - more resources